ATCC12228EVs decreased the expression of IL-36R and IL-36α but increased the IL-36Ra, suggesting that the mechanism of action for reducing imiquimod-induced psoriasis depends on the downregulation of the IL-36R signaling, in general attenuating the development of the psoriatic lesion. The gene discussed is IL1RL2; the disease is psoriasis.